Step inside the SynCardia Total Artificial Heart patient journey, from implant through recovery, and see how advanced mechanical circulatory support helps patients return to what matters most.
Missed it yesterday?
The first cardiovascular episode of The Crux of MedTech isn’t about products or markets. It explores what changes when a clinician becomes the patient—and how decisions are made when outcomes are uncertain.
🎧 https://t.co/8Blg8SKxBU
We honor Dr. Peter Heimes, whose invention of the Heimes Driver made portable support for Total Artificial Heart patients possible. His work inspired today’s Freedom Driver system. We carry forward his vision—saving lives, one heart at a time.
We’re headed to the AHA Scientific Sessions in Louisiana next week! #AHA25 ❤️
Visit Booth 3408 to connect with the @SynCardia team and learn how the Total Artificial Heart is helping give patients with end-stage heart failure a second chance at life.
Our @SynCardia Total Artificial Heart is featured on 9-1-1, now streaming on @Hulu!
Catch S6E1: “Let the Game Begin” and see life-saving innovation in action.
We had a wonderful time exhibiting at the @UCSF Update on Heart Failure Therapies 2025 in beautiful Sonoma, CA. Thank you to UCSF for hosting such a valuable gathering!
Join us in New York to hear from Patrick and learn more about how Picard Medical and SynCardia are driving innovation in advanced heart failure treatment.
🔗 Event info: https://t.co/RVO6bn0Fxb
SynCardia CEO Patrick NJ Schnegelsberg will speak at the H.C. Wainwright Global Investment Conference on Sept. 10 at 1:30 PM. Hear how we’re advancing the world’s only FDA-approved Total Artificial Heart.
https://t.co/RVO6bn0Fxb
SynCardia CEO Patrick NJ Schnegelsberg will speak at the H.C. Wainwright Global Investment Conference on Sept. 10 at 1:30 PM. Hear how we’re advancing the world’s only FDA-approved Total Artificial Heart.
https://t.co/RVO6bn0Fxb
SynCardia CEO Patrick NJ Schnegelsberg will speak at the H.C. Wainwright Global Investment Conference on Sept. 10 at 1:30 PM. Hear how we’re advancing the world’s only FDA-approved Total Artificial Heart.
https://t.co/RVO6bn0Fxb
Big smiles from our team at VADapalooza!
Proud to join other innovators in supporting VAD teams and the patients they care for.
#syncardia#syncardiacares
Helping students start strong. 💪📚
The SynCardia team donated supplies + field trip funds to Utterback Middle School last week.
Proud to give back; one backpack, one student at a time. ❤️
#SynCardia#backtoschool
Steve Zamojski and Mark Snider are connecting with cardiothoracic surgeons to share real-world insights and discuss how the SynCardia Total Artificial Heart (STAH) makes a difference in the lives of patients with end-stage biventricular heart failure.
https://t.co/LkGFhwWePt
SynCardia is honored to take part in the SACS Annual Meeting. This premier gathering brings together the nation’s leading cardiothoracic surgeons and healthcare professionals.
https://t.co/LkGFhwWePt
#SynCardia#PicardMedical#Givingthegiftoftime
SynCardia was conceived during America's original medical moonshots—the 1960s push to develop a Total Artificial Heart. Since then, we have turned that bold vision into something real, practical, and lifesaving.
https://t.co/J5sNRypMzO
Meet Lance — From Heart Failure to New Beginnings
Lance, once sidelined by heart failure, spent over two years supported by the SynCardia TAH. Now thriving with a donor heart, he co-founded Unique Beating Hearts to support others on similar journeys. 💙
#SynCardia
Today, SynCardia honors Juneteenth—a day marking the end of slavery and celebrating Black freedom and resilience. We remain committed to equity, representation, and access in healthcare and beyond.
#Juneteenth#FreedomDay#EquityInHealthcare#SynCardia#medtech
Think you know artificial hearts?
TRUE or FALSE?
1️. The SynCardia TAH replaces both ventricles and all four native heart valves.
2. After receiving a SynCardia TAH, patients must remain in the hospital
Answers:
✅ True
❌ False
#SynCardia
SynCardia is proud to participate in this week’s Gordon Research Conference “Incorporating Novel Device Designs, Treatment Strategies and Therapeutic Adjuncts into Mechanical Circulatory Support Therapy” in Barcelona, Spain.
#SynCardia#GordonResearchConference
Patrick NJ Schnegelsberg, CEO of SynCardia Systems, LLC, is taking the stage at DeviceTalks Minnesota!
Don’t miss Patrick’s session on the SynCardia TAH.
If you’re in Minneapolis, come join us and be part of the conversation!
#SynCardia#DeviceTalks